Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: GlobalData
$125.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Ligand Pharmaceuticals Inc Reaffirms FY 2013 Guidance; Issues Q2 2013 Guidance In Line With Analysts' Estimates


Wednesday, 8 May 2013 04:00pm EDT 

Ligand Pharmaceuticals Inc announced that it is affirming its previous 2013 financial forecast and expects total revenues to be between $43 million and $46 million, and earnings per diluted share to be between $0.47 and $0.51. For the second quarter of 2013, it expects revenues to be between $9.0 million and $9.5 million, and earnings per diluted share to be between $0.03 and $0.05. Earnings per share guidance does not include the effects of any increase or decrease in contingent liabilities. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $45 million and EPS of $0.46 for fiscal 2013; revenues of $9.10 million and EPS of $0.04 for the second quarter of 2013. 

Company Quote

52.96
1.17 +2.26%
26 Dec 2014